Home › Funds › Tetragon Partners GP Ltd › GLUE

Tetragon Partners GP Ltd position in GLUE

MONTE ROSA THERAPEUTICS INC · Health Care

Tetragon Partners GP Ltd reported holding 56,052 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$669K, representing 0.09% of its reported portfolio and ranking #31 among its reported holdings. Tetragon Partners GP Ltd has disclosed GLUE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)56.05K sh
Reported value held$668.70K
Portfolio Weight0.09%
First reportedQ2 2026
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How Tetragon Partners GP Ltd's GLUE position evolved

Tetragon Partners GP Ltd first disclosed a stake in GLUE in Q2 2026 at 56,052 shares (US$1.4M). Across 2 filings, Tetragon Partners GP Ltd held the position steady without any share-count change. The most recent filing (Q3 2026) shows 56,052 shares valued at US$669K.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 56.05K $1.36M New
Q3 2026 56.05K $668.70K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GLUE and 13F data

GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 60 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), Vestal Point Capital, LP (US$111.3M), BVF INC/IL (US$108.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GLUE

All GLUE fund holders →

FAQ

How long has Tetragon Partners GP Ltd held GLUE?

Tetragon Partners GP Ltd has disclosed GLUE holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Tetragon Partners GP Ltd's current position in GLUE?

As of Q3 2026, Tetragon Partners GP Ltd holds 56.05K shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $668.70K, representing 0.09% of its reported portfolio and ranking #31.

Has Tetragon Partners GP Ltd been buying or selling GLUE?

In the latest 13F filing (Q3 2026), Tetragon Partners GP Ltd held unchanged its position in GLUE.

Which other funds hold GLUE?

Other major institutional holders of GLUE include NEA Management Company, LLC, Vestal Point Capital, LP, BVF INC/IL, among 60 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.